Questions remain about the significance of the dose-response relationship between body mass index (BMI) and lung cancer (LC) risk. Pertinent studies were identified through a search in EMBASE and PUBMED from July 2014 until March 2015. The summary relative risk (SRR) and confidence interval (CI) were estimated. The dose-response relationship was assessed using a restricted cubic spline. The overall meta-analysis showed evidence of a nonlinear association between BMI and LC risk (Pnonlinearity < 0.001). The SRR were 0.98 (95%CI: 0.95–1.01) for 25 kg/m2, 0.91 (95%CI: 0.85–0.98) for 30 kg/m2 and 0.81 (95% CI: 0.72–0.91) for 35 kg/m2, with mild between-study heterogeneity (I2 = 5%). The results of the stratified analysis by gender were comparable to those of the overall meta-analysis. When stratified by smoking status, linear dose-response associations were observed for current smokers, ex-smokers and non-smokers (Pnonlinearity > 0.05), whereas the effects were attenuated when restricting analysis to non-smokers and at the point of 30 kg/m2, the SRR was 0.96 (95%CI: 0.86–1.07) for males and 0.95 (95%CI: 0.89–1.02) for females. This meta-analysis provides quantitative evidence that increasing BMI is a protective factor against LC. Keeping normal-to-moderate BMI should be prescribed as an evidence-based lifestyle tip for LC prevention in smokers.
Lung cancer (LC) is one of the most prevalent and deadliest human cancers. The average five-year survival rate after diagnosis is 16.3%1, so it is essential to emphasise the importance of LC prevention and knowledge of modifiable risk factors. The identification of environmental exposures predisposing individuals to the development of LC, such as tobacco smoking and air pollution2,3,4,5,6, is prevalent among good quality epidemiology studies that explain the majority of LC incidence. Notably, the complex interplay of aetiological and psychophysical factors is believed to modify the effect of respiratory carcinogens on LC initiation and prognosis7,8. Growing evidence indicates that LC is one outcome for which the role of BMI requires clarification8,9,10, but the results from epidemiological studies are sometimes conflicting.
Several observational epidemiological studies have shown that higher BMI correlates with a lower risk of LC6,7,8,11. Two recent meta-analyses have provided more evidence supporting the idea that excess weight could significantly decrease the risk of LC12,13. It has been hypothesised that excess body weight and obesity are protective factors against LC, especially in current and former smokers. Despite this, the inverse association between BMI and LC risk is often criticised due to inadequate adjustment for cigarette smoking11,14. Some observations failed to confirm this association9,15 and have even reported contradictory results16. Moreover, BMI had been found to be unrelated to LC when limited to non-smokers17,18. Thus, clarifying the association between BMI and the risk of LC stratified by smoking status has important public health implications.
No work to date has clarified the dose-response relationship between BMI and LC risk, not to mention the differences relative to the classification of smoking status. In addition, the previous meta-analysis was performed simply by combining the same categories of BMI across individual studies and the resulting conclusions have been questioned. We therefore carried out a dose-response meta-analysis of prospective cohort studies to provide a more precise evaluation for the potential association between BMI and LC risk. We particularly wanted to clarify potential modification by smoking status, as well as to investigate potential heterogeneity by subgroup and meta-regression analyses.
Literature search and selection
A comprehensive literature retrieval was conducted by using the databases PubMed (Medline) and Embase from 6th July 2014 until 13th July 2014. An updated secondary search was performed until 1st March 2015. Pertinent articles were identified by using the key words “body mass index,” “BMI,” “obesity,” “overweight,” “body size” or “body weight” combined with “lung cancer,” “lung neoplasm” or “lung carcinoma”. Additionally, we scrutinized references from relevant original papers and review articles to obtain other pertinent publications. No language restrictions were imposed. We followed the criteria and standard for conducting meta-analyses of observational studies and reporting the results19.
Inclusion and exclusion criteria
Three authors independently retrieved and assessed potentially relevant articles according to the prespecified selection criteria. Discrepancies between reviewers were solved by discussion. To be included, the study had to meet the following criteria: (a) published as an original article; (b) has definite description of BMI in kg/m2; (c) with cohort design; (d) investigators provided the following data: the number of cases, the total subjects or person-years and estimates of relative risk (RR) [hazard ratio (HR), rate ratio, or standardized incidence ratio] with 95% confidence intervals (95%CIs) for three or more quantitative categories of BMI. If the person-years were not reported, they were calculated through multiplying the number of subjects by mean follow-up duration20; if multiple articles were on the same study population, the one with complete design or larger sample size was finally selected. Additionally, when there were separate data for gender, smoking status, or lung cancer histology in one study, they were considered apart21.
Two reviewers designed and pilot-tested an ad hoc developed excel sheet for data extraction, which was eventually approved by the authors’ team. General information, study characteristics, participants’ characteristics, results as reported (including number of participants, reference population, estimates of RR with 95%CI for BMI categories), associated raw data for re-calculation (data checking) and any multivariate analyses adjustment factors (if applicable) were collected.
For each study, the median or mean value for each category of BMI was assigned to each corresponding estimate of RR. When the median or mean value per category was not obtained in the study, we assigned the mid-point of the upper and lower boundaries in each category as the average BMI. For open-ended categories, value equal to 0.83 (1/1.2) times the upper limit of the lowest category and equal to 1.2 times the lower limit of the highest category were consistently used22.
To assess study quality of the included studies, a 9-point scoring system according to the Newcastle-Ottawa Scale was used23. Two stars with respect to comparability of studies on the basis of the design and analysis. A high-quality study was defined as a study with ≥7 points.
In this meta-analysis, the relative risks (RRs) and 95%CIs were considered as the effect size for all studies. Because the incidence of LC is low, the HR from cohort studies is approximated to RR. Besides, we just included RR or HR based on the Cox proportional hazard model for statistical analysis. Thus we reported all risk estimate produced by current meta-analysis as RR for simplicity. We extracted the RRs from the maximally adjusted model to lower the risk of possible confounding.
We followed the WHO international classification and defined body mass categories as follows: underweight (BMI < 18.5 kg/m2), normal (BMI = 18.5–24.9 kg/m2), overweight (BMI = 25–29.9 kg/m2) and obesity (BMI ≥ 30 kg/m2). Normal group (BMI = 18.5–24.9 kg/m2) was considered as reference group13. We conducted separate meta-analysis for different levels of BMI. Summary relative risks (SRRs) and 95%CIs were calculated by using an inverse variance-weighted method24. Stratified analyses, if three or more studies were available per subgroup, were carried out. Heterogeneity between studies was quantitatively assessed by the Cochran Q test (P < 0.1, significant heterogeneity) and I2 statistic (I2 < 30%, no heterogeneity or marginal heterogeneity; I2 = 30–75%, mild heterogeneity; I2 > 75%, notable heterogeneity)25. DerSimonian and Laird random-effects models were applied when heterogeneity was significant; otherwise, a fixed-effects model was applied26. Further restricted maximum likelihood (REML) based random effects meta-regression analysis was conducted to investigate the sources of heterogeneity among studies according to the selected factors27.
A dose-response meta-analysis was performed to examine a potential nonlinear relationship between BMI and LC. We used restricted cubic splines with 3 knots at fixed 10%, 50% and 90% to model a potential curvilinear relationship and then a dose-response meta-analysis was conducted using the generalized least-squares trend command for summarised dose-response data28,29. The pooled RRs for specific BMI values were finally estimated (per 0.5 kg/m2 increase from BMI = 20 to 35 kg/m2) using the restricted maximum likelihood method in a multivariate random-effects meta-analysis30. A P value for non-linearity was computed by testing the null hypothesis that the coefficient of the second spline was equal to zero29. Further stratified analyses, if feasible, were performed according to sex, smoking status and histologic type, respectively. Moreover, we performed sensitivity analyses to assess whether the SRRs are robust to inclusion of studies31. Publication bias was evaluated with the use of the Begg and Egger’s test32. All statistical analyses were performed with Stata 10.0 software.
Search results and study characteristics
The detailed steps of our literature search are shown in Figure S1. Briefly, we identified 29 cohort studies of BMI and LC risk. These studies included 56,189 cases and 7,253,941 participants. Among the studies included, 14 studies provided RRs with 95%CIs for underweight, 29 for overweight and 29 for obesity. Meanwhile, 11 studies were conducted in the United States, nine in Europe and nine in Asia. Most studies controlled for age (27 studies) and smoking (26 studies). Nine and seven articles only reported separate outcomes of males and females, respectively and 13 articles reported the outcomes of both sexes. Of these 13 articles, five provided data of males and females combined, while eight reported outcomes of males and females separately. Detailed characteristics of the cohort studies, including study effect estimates, are provided in Table S1. Study-specific quality scores are summarised in Table S2. Overall, six studies had a score of 9, 12 had a score of 8, eight had a score of 7 and the three remaining studies had a score of 6.
Overall risk of LC and subgroup analysis
A total of 14 studies reported an association between being underweight (BMI < 18.5 kg/m2) and overall LC events. The SRR showed that being underweight, compared with the reference, was associated with an increased risk of LC (RR, 1.24; 95%CI: 1.20–1.27; Pheterogeneity = 0.17; Fig. 1a). Table 1 gives pooled RRs and corresponding 95%CIs of LC risk in those that are underweight versus the reference weight in the strata of selected factors. Interestingly, being underweight was not associated with risk of LC if the individuals were ex-smokers (RR, 1.39; 95%CI: 0.82–1.27) and non-smokers (RR, 1.18; 95%CI: 0.90–1.54). Additional stratified analyses were not performed according to histological types because of the lack of data.
The pooled RRs for the association between excess weight (BMI ≥ 25 kg/m2) and the risk of LC were 0.82 (95%CI: 0.77–0.86) for overweight (Fig. 1b) and 0.78 (95%CI: 0.74–0.83) for obesity (Fig. 1c). A significant heterogeneity between studies was found with overweight (Pheterogeneity = 0.02) and obesity (Pheterogeneity = 0.01). Therefore, we carried out subgroup analyses to identify sources of heterogeneity and minimise heterogeneity among eligible studies. As shown in Table 2, we noted that being overweight was unrelated to the risk of LC in the small cell carcinoma group (RR, 1.04; 95%CI: 0.91–1.18). Furthermore, when the analysis was restricted to the three studies that had a NOS score of 6, the pooled RR was 1.10 (95%CI: 0.88–1.39). For the category of obesity, the results of the stratified analyses are also presented in Table 2. The association of obesity with lower LC risk was consistent in all subgroups except for the small cell carcinoma group (RR, 0.84; 95%CI: 0.56–1.26) and having the number of LC cases ≤ 200 (RR, 0.79; 95%CI: 0.58–1.08).
Overall dose-response association between BMI and risk of LC
For the dose-response analysis, data from 26 studies (only high-quality studies) were used, including 43,393 LC cases. The SRR and 95%CI of LC per five-unit increment in BMI were 0.97 (95%CI: 0.96–0.98) with significant heterogeneity (I2 = 60.5%, Pheterogeneity < 0.01). As shown in Fig. 2a, we found evidence of a nonlinear relationship between BMI and overall LC risk (Pnonlinearity < 0.01, I2 = 5%). Moreover, this dose-response trend showed a statistically significant decreased risk of developing LC with increasing BMI. Note that several representative point values are presented in Table 3. In a sensitivity analysis iteratively omitting each study from the overall analysis, a significant nonlinear dose-response relationship between BMI and overall risk of LC still remained and the point estimation of BMI did not substantially change, suggesting high level of stability for the current result.
After stratifying by sex, the non-linear relationship between BMI and LC risk was observed in both subgroups (all Pnonlinearity < 0.05; Fig. 2b,c, respectively). After stratifying by smoking status, it is worthwhile to note that no evidence of a nonlinear association was observed in current smokers, ex-smokers and non-smokers (all Pnonlinearity > 0.05, Fig. 2d–f, respectively). We also performed a stratified analysis by sex based on smoking status, apart from female current smokers and a statistically linear association between BMI and LC risk was observed in the rest of the groups (all Pnonlinearity > 0.05). After stratifying by histologic type, there was a significant nonlinear association between BMI and lung adenocarcinoma risk (Pnonlinearity < 0.01, Fig. 2g).
For non-smokers, it is noteworthy that the SRRs of LC risk were 0.96 (95%CI: 0.91–1.01) at the point of 30 kg/m2, 0.94 (95%CI: 0.81–1.08) at 35 kg/m2 and 0.92 (95%CI: 0.72–1.17) at 40 kg/m2. For male non-smokers, the SRRs of LC risk were 0.96 (95%CI: 0.86–1.07) at the point of 30 kg/m2 and 0.95(95%CI: 0.71–1.27) at 35 kg/m2. For female non-smokers, the SRRs of LC risk were 0.95 (95%CI: 0.89–1.02) at the point of 30 kg/m2 and 0.95 (95%CI: 0.76–1.10) at 35 kg/m2. A sensitivity analysis for non-smokers was also conducted. Excluding those that were not controlled for potential confounders, none of the point estimates were materially altered, indicating that our results were robust.
Sources of heterogeneity and publication bias
For studies of those that were overweight, we found no significant heterogeneity between studies when stratified by the number of cases or study quality scores (Table 2). In multivariate meta-regression analyses, the combination of four variables (including sex, body size assessment, the number of cases and study quality score) was statistically significant. The between-study variance was reduced from 0.008 to 0.001 based on the REML estimate and the heterogeneity explained by these four variables was 88.24%. In studies of obesity, the number of cases was identified as being a major source of heterogeneity between studies (P = 0.04) and the between-study variance was reduced from 0.008 to 0.000. The heterogeneity explained by the number of cases was 98.70%. In addition, the visual inspection of the Begg’s funnel plot or Egger’s plot revealed symmetry (Fig. 3) and there was no significant publication bias detected by the Begg’s and Egger’s tests (P = 0.09 for underweight, 0.70 for overweight, 0.23 for obesity).
The present meta-analysis is the first to provide comprehensive and quantitative evidence of the dose-response association between BMI and LC risk. We found that lower BMI was associated with higher LC risk and each 5 kg/m2 increment of BMI corresponded to a 3.3% decrease in the risk of LC. BMI was inversely nonlinearly associated with overall LC risk. The reduction affects men and women alike and it was greater for obesity than for overweight, displaying a significant nonlinear dose-response relationship. Note that the subgroup results of the dose-response analysis should be interpreted with caution because only a few studies focused on the histologic subtypes of LC and interestingly, significant linear relationships that might result from heterogeneity and residual confounding were observed in current smokers, ever-smokers and non-smokers, respectively.
One of the previous meta-analyses showed a negative association of 0.79 (95%CI: 0.73–0.85) between the risk of LC and excess weight (BMI ≥ 25 kg/m2)12. Moreover, Renehan et al. reported that a 5 kg/m2 increase in BMI was inversely associated with LC risk and the pooled RRs were 0.76 (95%CI: 0.70–0.83) for men and 0.80 (95%CI: 0.66–0.97) for women13. This is in line with our results. As overweight/obesity was closely related to a lower risk of LC, we proposed the hypothesis that being underweight was related to a higher risk of LC. In our meta-analysis, indeed, being underweight was associated with an increased risk of LC. We also found that being underweight might not exert an inverse effect on modulating LC risk in ex-smokers and those that have never smoked. In addition, the results showed no evidence of publication bias in the overall and stratified analyses for underweight, which indicated a good representation of the extracted studies. The observed underweight–LC association in the present study, if validated in future studies, has relevance for public health.
Previously published systematic reviews, investigating overweight/obesity and risk of LC, were both based on the cohort and case-control studies. The inherent limitation was that the cut points for BMI differed between the included studies and information bias in case-control studies was of particular concern, especially for smoking. It is essential to clarify the shape of the dose-response curve, as inconsistencies in the results between studies relate to different BMI levels. It is possible that only current smokers or ever smokers may benefit from excess weight and the implications for those individuals with moderate or high BMI status that smoke may be different. Moreover, some uncertainties may be present in the extrapolation from low to high BMI in a nonlinear dose-response association and therefore, demanding caution for LC prevention. Hence, we conducted a dose-response meta-analysis of cohort studies to evaluate the optimal range of BMI. We found BMI had a negative association with incidence of LC in men and in women. In light of our findings, the current guidelines for lowering the risk of LC among the general population may be revised to recommend 18.5 < BMI < 30 kg/m2 and meanwhile, avoiding obesity is also necessary considering that obesity increases the risk of certain cancers and cardiovascular disorders33, a relationship that has already been confirmed.
Confounding variables represent a primary issue in observational aetiological studies. The finding that obesity has been associated with a reduced LC risk may be due to the confounding caused by smoking, because smoking habits affect both body weight and body composition34,35. The general BMI–smoking interaction is considerably complex and is subject to change over time. Importantly, obesity in relation to lung cancer in non-smokers is difficult to interpret. Present study investigating BMI–LC associations has conventionally stratified for smoking status. Strong inverse association was observed between BMI and the risk of lung cancer among former and current smokers. However, the findings from our current dose-response meta-analysis suggest that increased BMI has a negligible effect on the risk of LC in non-smokers and obesity was not significantly associated with risk of LC. Meanwhile, it appears that the results of the subgroup analysis according to females and males were due to smoking status, particularly among current smokers. Since increased BMI is associated with decreased LC risk in smokers and no association was found in non-smokers, one could, of course, speculate that the decreased risk of LC has been driven less by excess body weigh in non-smokers, or that only smokers benefit more from obesity in terms of lowered risk of LC. It is implied that an effect of BMI on lung cancer is independent of smoking status. Although we cannot rule out the effect of uncontrolled confounding by smoking, We can be certain that the overall impact of BMI–smoking on LC risk is comparably apparent and suitable body weight as well as the smoking control is by far the very efficient measure to prevent LC.
The theoretical biological plausibility for the negative association between obesity and LC risk is as follows. (1) Possible plausibility exists through the effect of adipose tissue on storage, mobilisation and metabolism of carcinogen-DNA adducts36,37. Both 8-hydroxydeoxyguanosine (8-OHdG) and benzo(a)pyrene (BaP) adduct, for example, are the most frequently encountered carcinogen-DNA adducts38. Studies had found a significant inverse association between BMI and BaP adduct, urinary levels of 8-OHdG39,40. (2) Excess body fat is linked to elevated production of insulin, resulting in the increase of insulin–like growth factor I and secretion of sex steroids, which subsequently promotes cell proliferation and suppresses apoptosis and thus improve immune function and inhibit carcinogenesis41,42. Moreover, studies that have shown reduced risks of lung cancer associated with the use of menopausal hormones have contributed to speculations that oestrogens may exert beneficial effects against LC43,44,45. Actually, several studies had found a positive association between BMI and serum oestrogen levels and adipose tissue is the primary site for oestrogen synthesis45,46. (3) Brennan et al. reported that obesity associated with the gene (FTO) A allele, which was proven to correlate with increased BMI, was also associated with a decreased risk of LC47,48. The biological mechanisms behind such a negative obesity–LC link remains unclear and thus, better designed molecular–epidemiologic studies and further work in exploring the underlying carcinogenic mechanism are necessary.
A notable strength of the present methodology is the trend estimation of the summarised dose-response data, not only offering uniform analysis of cohort studies with different BMI categories and analysis of studies across varied levels of BMI, but also offering greater power using the full spectrum of continuous BMI data. Several limitations in our review should be mentioned. (1) There are several methodological limitations (including BMI assessment and analytic methodology) that are worth consideration. (2) Unmeasured and residual confounding variables might bias the results toward the exaggeration or underestimation of risk estimates. Because of the inability to fully adjust for confounders, the protective effect of increasing BMI on LC could be attributed to other favourable lifestyle factors. (3) Due to the limitation of eligible data, the subgroups based on smoking status were crudely classified into current smoking, ex-smoking and non-smoking subgroups, regardless of the smoking duration, cumulative smoking exposure and smoking intensity. (4) High heterogeneity across studies was presented for the overweight–LC and obesity–LC links, which would throw some doubts on the reliability of the SRR estimates. (5) Only studies published in the electronic edition of the databases in the English and Chinese languages have been reviewed for pertinence and studies in other languages were omitted. Despite these limitations, the meta-analysis included a substantial number of cohort studies, which greatly enhanced the statistical power of the analysis and provided enough evidence for the authors to draw a reliable conclusion.
In summary, our meta-analysis contributes to the literature by exploring the nonlinear dose-response relationship between BMI and the risk of LC. An inverse dose-response relationship is likely to be present for LC risk with increasing BMI. Being underweight was strongly associated with increased risk of LC. Excess weight provides a potential protective effect against LC. However, the results from dose-response analyses in non-smokers support the idea that BMI has a modifying effect on smoking-related LC risk. Studies with large-scale, longer follow-up times and studies that are well-designed are warranted to confirm these subgroup results.
How to cite this article: Duan, P. et al. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci. Rep. 5, 16938; doi: 10.1038/srep16938 (2015).
Marshall, A. L. & Christiani, D. C. Genetic susceptibility to lung cancer–light at the end of the tunnel? Carcinogenesis 34, 487–502 (2013).
Raaschou-Nielsen, O. et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 14, 813–822 (2013).
Leung, C. C. et al. Lower lung cancer mortality in obesity. Int J Epidemiol 40, 174–182 (2011).
Buettner, R., Wolf, J. & Thomas, R. K. Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment. J Clin Oncol 31, 1858–1865 (2013).
Wen, J., Fu, J. H., Zhang, W. & Guo, M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Modern Pathol 24, 932–943 (2011).
Houghton, A. M. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13, 233–245 (2013).
Tarnaud, C. et al. Body mass index and lung cancer risk: results from the ICARE study, a large, population-based case-control study. Cancer Cause Control 23, 1113–1126 (2012).
Smith, L. et al. Body Mass Index and Risk of Lung Cancer Among Never, Former and Current Smokers. Jnci-J Natl Cancer I 104, 778–789 (2012).
Parr, C. L., Batty, G. D. & Lam, T. H. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration pooled analyses of 424 519 participants (vol 11, pg 741, 2010). Lancet Oncol 11, 721–721 (2010).
El-Zein, M. et al. Body mass index, lifetime smoking intensity and lung cancer risk. Int J Cancer 133, 1721–1731 (2013).
Kabat, G. C., Kim, M., Hunt, J. R., Chlebowski, R. T. & Rohan, T. E. Body mass index and waist circumference in relation to lung cancer risk in the Women’s Health Initiative. American journal of epidemiology 168, 158–169 (2008).
Yang, Y. et al. Obesity and incidence of lung cancer: A meta-analysis. Int J Cancer 132, 1162–1169 (2013).
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies. Am J Health Promot 23, 153–153 (2008).
Koh, W. P., Yuan, J. M., Wang, R., Lee, H. P. & Yu, M. C. Body mass index and smoking-related lung cancer risk in the Singapore Chinese Health Study. British journal of cancer 102, 610–614 (2010).
Jee, S. H. et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 123, 1892–1896 (2008).
Kabat, G. C., Miller, A. B. & Rohan, T. E. Body mass index and lung cancer risk in women. Epidemiology 18, 607–612 (2007).
Henley, S. J., Flanders, W. D., Manatunga, A. & Thun, M. J. Leanness and lung cancer risk: fact or artifact? Epidemiology 13, 268–276 (2002).
Lam, T. K. et al. Anthropometric measures and physical activity and the risk of lung cancer in never-smokers: a prospective cohort study. PloS one 8, e70672 (2013).
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery 8, 336–341 (2010).
Zou, L. et al. Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: Evidence from a meta-analysis of 42 observational studies. Eur J Cancer 50, 193–203 (2014).
Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting. Jama-J Am Med Assoc 283, 2008–2012 (2000).
Orsini, N. & Greenland, S. A procedure to tabulate and plot results after flexible modeling of a quantitative covariate. Stata J 11, 1–29 (2011).
Wells GA, S. B. et al. (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. (Date of access: 03/10/2015).
Wang, F. & Xu, Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. Int J Cancer 135, 1673–1686 (2014).
Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Bmj 327, 557–560 (2003).
DerSimonian, R. & Kacker, R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials 28, 105–114 (2007).
Jackson, D., White, I. R. & Riley, R. D. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31, 3805–3820 (2012).
Harrell, F. E., Jr., Lee, K. L. & Pollock, B. G. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst 80, 1198–1202 (1988).
Orsini, N., Bellocco, R. & Greenland, S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 6, 40–57 (2006).
Jackson, D., White, I. R. & Thompson, S. G. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 29, 1282–1297 (2010).
Patsopoulos, N. A., Evangelou, E. & Ioannidis, J. P. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. International journal of epidemiology 37, 1148–1157 (2008).
van Enst, W. A., Ochodo, E., Scholten, R. J., Hooft, L. & Leeflang, M. M. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC medical research methodology 14, 70 (2014).
World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Available at: http://www.dietandcancerreport.org/. (Date of access: 03/12/2015).
Zhu, K. et al. Body mass index and breast cancer risk in African American women. Annals of epidemiology 15, 123–128 (2005).
Felson, D. T. & Zhang, Y. Smoking and osteoarthritis: a review of the evidence and its implications. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 23, 331–333 (2015).
Godschalk, R. et al. Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking. Carcinogenesis 23, 2081–2086 (2002).
Vineis, P. & Perera, F. DNA adducts as markers of exposure to carcinogens and risk of cancer. Int J Cancer 88, 325–328 (2000).
Garcon, G. et al. Benzo(a)pyrene-coated onto Fe2O3 particles-induced lung tissue injury: role of free radicals. Cancer Lett 167, 7–15 (2001).
Godschalk, R. W. L., Feldker, D. E. M., Borm, P. J. A., Wouters, E. F. M. & Van Schooten, F. J. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidem Biomar 11, 790–793 (2002).
Rundle, A. et al. The association between benzo[a]pyrene-DNA adducts and body mass index, calorie intake and physical activity. Biomarkers 12, 123–132 (2007).
Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4, 579–591 (2004).
Song, X. et al. Body mass index and cancer incidence: the FINRISK study. Eur J Epidemiol 29, 477–487 (2014).
Siegfried, J. M., Hershberger, P. A. & Stabile, L. P. Estrogen Receptor Signaling in Lung Cancer. Semin Oncol 36, 524–531 (2009).
Xu, L., Liao, Y., Tang, H., Zhang, C. & Liu, Z. [Advances of targeted therapy based on estrogen receptor signaling pathway in lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 14, 727–732 (2011).
Chakraborty, S., Ganti, A. K., Marr, A. & Batra, S. K. Lung cancer in women: role of estrogens. Expert review of respiratory medicine 4, 509–518 (2010).
Lukanova, A. et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. European journal of endocrinology / European Federation of Endocrine Societies 150, 161–171 (2004).
Brennan, P. et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. International journal of epidemiology 38, 971–975 (2009).
Leung, C. C. et al. Lower lung cancer mortality in obesity. International journal of epidemiology 40, 174–182 (2011).
This work was supported by National Natural Science Foundation of China (Grant Nos. 81172623 and 81372960).
The authors declare no competing financial interests.
Electronic supplementary material
About this article
Cite this article
Duan, P., Hu, C., Quan, C. et al. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci Rep 5, 16938 (2015). https://doi.org/10.1038/srep16938
Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study
BMC Medicine (2022)
BMC Cancer (2022)
Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain
BMC Medicine (2021)
Statistical Assessment of Toxic and Essential Metals in the Serum of Female Patients with Lung Carcinoma from Pakistan
Biological Trace Element Research (2020)
European Journal of Nutrition (2020)